Despite Myrexis' Appeal As A Value Investment, More To Consider
Brian L. Wilson
•
Wed, Jul 18, 2012
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
124 people get MYRX articles and Market Currents by email alert.
Get email alerts on MYRX »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
5 Stocks Trading Below Net Cash - Part VIIIMarkus Aarnio • Mon, Sep 3, 2012 -
-
-
-
-
Insider Buying Trends: Are These Cash-Rich Companies Ready For A Rally?Kapitall • Sun, May 20, 2012
-
-
-
-
2 Pharma Stocks Under $5 Trading Below CashAlex Shadunsky • Tue, Jul 12, 2011 -
-
-
-
-
-
FDA, Clinical Trial News: Discovery Labs, Hospira, Javelin PharmaMike Havrilla • Thu, May 20, 2010
-
-
-
-
There are no Transcripts on MYRX.
-
GlobeNewswire (Jan 23, 2013)
-
GlobeNewswire (Nov 9, 2012)
-
GlobeNewswire (Sep 13, 2012)
-
GlobeNewswire (May 11, 2012)
-
GlobeNewswire (May 10, 2012)
-
at MarketWatch.com (May 19, 2010)
-
at MarketWatch.com (May 18, 2010)
-
at MarketWatch.com (May 18, 2010)
MYRX vs. ETF Alternatives
Company Description
Currently, there's no company description for MYRX.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Tuesday, February 19, 12:53 PM
Midday top 10 gainers: NVGN +134%. PVFC +53%. CMGE +42%. TELOZ +41%. EMITF +37%. ZIPR +24%. RRGB +20%. OMX +20%. GSB +18%. LOAN +18%.
Midday top 10 losers: MYRX -95%. CPSL -35%. GMXR -29%. DGIT -25%. SNFCA -20%. EHTH -17%. CIMT -16%. RVLT -13%. MARK -13%. PERY -12%. Comment! [On the Move] - Wednesday, January 23, 10:44 AM Myrexis (MYRX +4%) trades up after saying that its board of directors has has decided to no longer pursue its previously announced plan of complete liquidation and dissolution, and has cancelled the special meeting of its shareholders. The board plans to instead implement new arrangements, including the declaration of a special cash distribution to shareholders of $2.86 per share, payable to shareholders of record at the close of business on Feb 4. Comment! [Healthcare, On the Move]
- Monday, November 12, 2012, 12:45 PM Midday top 10 gainers: TIE +42%. STV +32%. MYRX +18%. CPSS +17%. PZZI +15%. SRPT +13%. EVI +13%. JEF +12%. GILD +12%. CXS +12%. Midday top 10 Losers: CLVS -33%. GALE -33%. STSI -23%. RECV -17%. BZH -15%. ET -14%. XIDE -13%. NKTR -12%. MEET -12%. IDN -11%. Comment!
-
Monday, November 12, 2012, 9:10 AM
Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
Losers: CLVS -41%. STSI -20%. NBG -11%. Comment! [On the Move] -
Friday, November 9, 2012, 5:45 PM
After-hours top gainers, as of 5:15 p.m.: MYRX +23.5%. NXTM +6.5%. BGCP +5.4%. IO +5.3%. MSCC +4.7%.
After-hours top losers: STSI -10.2%. PEGA -7.5%. ENR -7%. WG -6.7%. EXEL -6%. 1 Comment [On the Move] - Friday, November 9, 2012, 4:33 PM Myrexis (MYRX) says its Board of Directors has opted, subject to shareholder approval, to dissolve the company and liquidate its assets. The company intends to distribute all available cash, except such cash as is required for paying or making reasonable provision for known and potential liabilities and other obligations of the company. The board is calling a special meeting of the shareholders to seek approval, and will file proxy materials with the SEC as soon as practicable. Comment! [Healthcare]
- Thursday, September 13, 2012, 4:39 PM Myrexis (MYRX) suspends development activity on all its programs, saying it's been unsuccessful to date in identifying and attracting third parties to whom it could out-license or sell assets for further development. In February, the company announced that it had suspended development activity on all of its preclinical and clinical programs, and retained Stifel Nicolaus Weisel to assist in reviewing and evaluating strategic alternatives. Comment! [Healthcare]
- Friday, November 18, 2011, 4:11 PM Biotech developer Myrexis (MYRX +1.2%) bucks a weak tape to close higher after it announces plans to reduce its workforce by 20% in its second restructuring this year, a move prompted by its September suspension of the development of then-lead drug candidate Azixa. Comment! [Healthcare, On the Move]
- Friday, September 9, 2011, 1:01 PM Myrexis (MYRX -2.8%) is down today after after reporting a wider FQ4 loss and saying it's suspended any further development of its lead drug candidate Azixa. Comment! [Healthcare, On the Move]
- Monday, April 12, 2010, 10:17 AM Javelin Pharmaceuticals (JAV +61.2%) delivers a notice of intent to terminate its merger agreement with Myriad Pharmaceuticals (MYRX +7.1%) after receiving a buyout offer from Hospira (HSP -0.2%) for $2.20 per share. (PR) Comment!
-
freefdawatchlist
http://bit.ly/W2uOeA Stocks for Nov 12th: $AAPL,$PCP, $MYRX, $FSYS, $SIM, $STSI, $SQNM, $MCP - View all 0 replies
-
Michael Kudrna
Biotech: Myrexis (MYRX) AACR-NCI-EORTC Conference Abstracts & Commentary http://bit.ly/vFyFVZ/ - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Justin M. Hall
Rx Investors' Brain Cancer Index ==> AGEN, CLDX, MYRX, NWBO, PPHM, EXEL ==> http://bit.ly/bxkxgm/ - View all 0 replies
-
Justin M. Hall
Rx Investors' HSP-90 & Hedge Hog Pathways Index ==> INFI, MYRX, SNTA,CRIS ==> http://bit.ly/bxkxgm/ - View all 0 replies
-
Danny Furman
JAV pops 60%+ on termination of merger with MYRX. Good enough for me, JAV position closed. - View all 0 replies
-
- View all 1 replies
-
gmacd: Hey I saw that MYRX paid out a dividend of ~$3/sh earlier this month. Did you hold on?
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
gmacd: Hey I saw that MYRX paid out a dividend of ~$3/sh earlier this month. Did you hold on?